Celltrion

Celltrion said it set up a dedicated AI-based new-drug organization the previous year and is applying AI in stages, with bioinformatics, to finding, validating and optimizing new-drug target candidates. The release also says the company is pursuing open innovation with external AI specialist firms, which it does not name.

Celltrion said manufacturing work is focused on smart factories that apply physical AI at new plants. It said it plans to raise automation at drug-substance plants 4 and 5, which are to be built in Songdo, with autonomous mobile robots, an automated warehouse, intelligent and collaborative robot arms, and manufacturing-management software.

Celltrion said it is already using AI in office work for data analysis, building dashboards and drawing insights, and that it will widen that use. A chatbot simulation on the electronic document system projected that time for simple tasks such as document search and comparison would be about 80 to 90 percent shorter.

At the 2024 J.P. Morgan Healthcare Conference, Celltrion said its CEO shared plans to expand into digital healthcare with a company-owned data bank. That bank would use artificial intelligence to synthesize Celltrion's clinical and genomic data.